University of Oxford
University of Oxford is named in the Raise Track Update as an investor in Alethio Therapeutics and FluoRok.
- Type
- Venture capital firm
About
University of Oxford participated in Alethio Therapeutics' $90 million Series A and FluoRok's $30 million Series A, both announced on 2026-11-05. Both companies are Oxford spin-outs.
This page is not indexed by search engines yet. It is promoted once it meets the quality gate for investor pages: a description from the firm's own website, a headquarters city and at least two two-sourced rounds on this site.
Funding rounds on RaiseTrack
| Company | Round | Date | Role |
|---|---|---|---|
| Alethio Therapeutics | Series A 2026 | 2026-11-05 | participant |
| FluoRok | Series A 2026 | 2026-11-05 | participant |
Sources
Last verified:
- https://alethiotherapeutics.com/alethio-therapeutics-raises-90-million-67-million-in-oversubscribed-series-a-financing-to-advance-a-new-generation-of-therapies-for-myeloproliferative-neoplasms/
Type: company announcement. Accessed 2026-11-05.
Alethio Therapeutics release, 5 November 2026. Names the University of Oxford among the backers of the $90 million Series A. Says Alethio spun out from the University of Oxford. - https://www.fluorok.com/news/fluorok-raises-30m-series-a
Type: official company website. Accessed 2026-11-05.
FluoRok news post, Nov 5, 2026. Names the University of Oxford among existing investors in the $30 million Series A and says FluoRok was spun out from the university. - https://buttondown.com/raisetrack/archive/raise-track-update-2026-11-05/
Type: other verified public source. Accessed 2026-11-05.
Raise Track Update for 2026-11-05. Names University of Oxford in Alethio Therapeutics and FluoRok.